WASHINGTON, Oct. 1, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) announced today during their Annual Scientific Meeting the launch of a new journal, JCF-Intersections (JCF-I), in partnership with Elsevier. This new journal will join the JCF Family of Journals, led by…
Other News
Conformal Medical Announces Launch of the GLACE Study with Next-Gen CLAAS® AcuFORM™ Left Atrial Appendage Occlusion Device
Study will assess the Company’s Next-Generation device under Intracardiac Echocardiography (ICE) imaging for Left Atrial Appendage Occlusion (LAAO) procedures. NASHUA, N.H., Oct. 1, 2024 /PRNewswire/ — Conformal Medical, Inc. today announced the initiation of the GLACE Study. This…
Remedy Pharmaceuticals’ Phase 3 Trial in Large Lesion Stroke Patients Demonstrates Statistically Significant Effect at One Year
NEW YORK, Oct. 1, 2024 /PRNewswire/ — Remedy Pharmaceuticals today announced additional promising data from the Phase 3 CHARM clinical trial of CIRARA (IV glyburide) in patients with Large Hemispheric Infarction (LHI), the most serious form of ischemic stroke, characterized by…
Synchron Announces Positive Results from U.S. COMMAND Study of Endovascular Brain-Computer Interface
NEW YORK–(BUSINESS WIRE)–Synchron, a brain-computer interface company, today announced positive results from the COMMAND study evaluating the safety and efficacy of the Synchron brain computer interface (BCI) device in six participants over a 12-month period. “The COMMAND study results represent a major medical milestone, confirming the safety of the Stentrode […]
Pi-Cardia Receives FDA Market Clearance for ShortCut™
REHOVOT, Israel–(BUSINESS WIRE)–Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market clearance for ShortCut™ – the world’s first dedicated leaflet modification device, enabling valve-in-valve Transcatheter Aortic Valve Replacement (TAVR) procedures […]
Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related Heart Failure
– Results from the placebo-controlled study in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) were presented in a Late Breaking Clinical Trial Plenary Session at the HFSA Annual Scientific Meeting 2024 – – Data showed patients treated with HU6…
HeartX Cardiovascular Accelerator Announces Four Startup Companies Selected for the 2024 Program
BENTONVILLE, Ark., Sept. 30, 2024 /PRNewswire/ — HeartX, powered by HealthTech Arkansas and MedAxiom — along with numerous leading cardiology practices in Arkansas and around the country — has selected four startup healthcare companies to participate in its 2024 accelerator program….
Argon Medical Announces the Expansion of Liver Management Portfolio with Two New Product Introductions
PLANO, Texas, Sept. 30, 2024 /PRNewswire/ — Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the Intara™ Introducer Sheath and the TLAB®…
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
Cortechs.ai Announces Strategic Partnership with Ascend Imaging to Expand Access to Cutting-Edge Radiology Solutions
SAN DIEGO, Sept. 30, 2024 /PRNewswire/ — Cortechs.ai, a leader in advanced imaging software medical analysis, is proud to announce a strategic partnership with Ascend Imaging, a premier provider of radiology products and services. This collaboration will enhance Cortechs.ai’s ability to…



